Comparative Pharmacology
Head-to-head clinical analysis: ORGOVYX versus ORILISSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORGOVYX versus ORILISSA.
ORGOVYX vs ORILISSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) receptor antagonist; competitively blocks GnRH receptors in the anterior pituitary, rapidly reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to suppression of testosterone production.
Elagolix is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively inhibits GnRH binding to pituitary GnRH receptors, resulting in suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing ovarian sex hormone production.
120 mg orally three times daily (total daily dose 360 mg). Administer with a low-fat meal (<30% fat) to reduce gastrointestinal adverse effects.
100 mg orally once daily for endometriosis; 200 mg orally twice daily for uterine fibroids.
None Documented
None Documented
Terminal elimination half-life is approximately 28.6 hours (range 22–36 hours) in patients; supports once-daily dosing with steady state achieved by day 7.
Terminal elimination half-life is approximately 6.5 hours (range 4–9 hours) in healthy subjects; clinical effect in endometriosis requires daily dosing.
Primarily hepatic metabolism; approximately 21% of dose recovered as unchanged drug in urine, with ~80% recovered as metabolites in feces over 7 days.
Approximately 86% of the dose is excreted in feces (as unchanged drug and metabolites) and about 20% in urine (primarily as metabolites). Renal elimination of unchanged drug is <1%.
Category C
Category C
GnRH receptor antagonist
GnRH receptor antagonist